PATENT CLAIM ANALYSIS

Application Number: 15903671
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["514", "248000"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Claim (Index 18):
The method according to  claim 16 , wherein R 10  in Formula (VII) is independently selected from F, Cl, CF 3 , and CHF 2 .

Metadata:
- Claim Count in Document: 4.0
- Percentile: 88.0
- Lexical Diversity: 1.27778
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14872546', '15115314', '15747867', '15205059', '15735322']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8296765334649155
- 35 USC 102 Novelty (BERT): 0.6117427333341322
- Combined Prediction Score: 0.8078831534518371
- Mean Citation Score: 526.2841340000001
- Max Citation Score: 598.2743
- Similarity Product: 460.0329582130552

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test